Hematologic effects of linezolid: summary of clinical experience

Antimicrob Agents Chemother. 2002 Aug;46(8):2723-6. doi: 10.1128/AAC.46.8.2723-2726.2002.

Abstract

Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at > or =2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.

MeSH terms

  • Acetamides / adverse effects*
  • Anemia / blood*
  • Anemia / chemically induced*
  • Anti-Infective Agents / adverse effects*
  • Blood Cell Count
  • Clinical Trials as Topic
  • Hemoglobins / metabolism
  • Humans
  • Linezolid
  • Neutropenia / blood
  • Neutropenia / chemically induced
  • Oxazolidinones / adverse effects*
  • Retrospective Studies
  • Thrombocytopenia / blood
  • Thrombocytopenia / chemically induced

Substances

  • Acetamides
  • Anti-Infective Agents
  • Hemoglobins
  • Oxazolidinones
  • Linezolid